AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024 https://ow.ly/69xq50TE8rF
AbCellera
Biotechnology Research
Vancouver, British Columbia 35,662 followers
Antibody discovery engine
About us
AbCellera discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners.
- Website
-
http://www.abcellera.com
External link for AbCellera
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Vancouver, British Columbia
- Type
- Public Company
- Founded
- 2012
- Specialties
- Antibody Discovery, Cell Culture, Antibody Therapies, Protein Analysis, Microfluidic Single Cell Analysis, Single Cell Genomics, Monoclonal Antibody Discovery, Cell Enrichment, Cell Screening, Cell Recovery, Protein engineering, T cell engagers, and Bispecifics
Locations
-
Primary
2215 Yukon St
Vancouver, British Columbia V5Y, CA
-
91 Mystic St
Arlington, Massachusetts 02474, US
-
41-45 Bourke Rd
Alexandria, New South Wales 2015, AU
-
7236 Rue Waverly
Montreal, Quebec H2R 0C2, CA
Employees at AbCellera
Updates
-
We’re excited to announce the publication of our review article in mAbs. The review highlights the critical aspects of developability assessment, and provides guidance on how to develop a comprehensive plan tailored to a given bispecific or multispecific to bring these innovative medicines to the clinic. Read the review here: https://ow.ly/u0qt50TwHNC
-
GPCRs are high-value targets that have been largely intractable to conventional antibody discovery technologies. Visit our poster at Discovery on Target to see how we generated and optimized multiple high-quality antibodies against a GPCR. #BostonDOT24 #drugtarget
-
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024 https://lnkd.in/gWTMYpmm
-
AbCellera to Present at Upcoming Investor Conferences in September https://ow.ly/946K50Tabxg
-
AbCellera Reports Q2 2024 Business Results https://ow.ly/9Oz150SSsxp
-
AbCellera and Eli Lilly and Company Expand Collaboration to Develop Antibody Medicines https://ow.ly/pPuy50SO4Te
-
Congratulations to our partner Invetx on its upcoming acquisition by Dechra Pharmaceuticals, a global leader in animal health. We're proud to be a founding partner in Invetx, and collaborating with it to discover innovative therapeutic antibodies for animals. https://lnkd.in/gWZgvhnM
-
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024 https://ow.ly/CNZx50SpyNJ